Amerika yakoze ibinini bigabanya ibiro

Ikigo cya leta y’Amerika gishinzwe kugenzura imiti n’ibiribwa (FDA) cyemeje ko Wegovy, umuti ukoreshwa mu kugabanya ibiro nk’uko byatangajwe n’ikigo gikomeye mu gutanga imiti cya Novo Nordisk.

Ibi binini bya mbere byo muri ubu bwoko byemejwe n’iki kigo gishinzwe kugenzura imiti, bikaba bifatwa nk’intangiriro y’igihe gishya mu miti yo kugabanya ibiro.

Novo Nordisk, ikigo cyo muri Danemark gikora Wegovy, cyavuze ko ibi ninini bifatwa rimwe ku munsi ari uburyo bworoshye ugereranyije n’ibyo baterwaga mu nshinge, kandi ko itanga igabanuka ry’ibiro ringana n’iry’imiti iterwa mu nshinge.

Ibi bije nyuma y’uko Wegovy yari imaze kwemezwa na FDA by’umwihariko nk’umuti wo kugabanya ibiro.

Indi miti nka Ozempic, ifite umumaro umwe wo kugabanya ibiro, yo yemejwe mbere na mbere nk’umuti wo kuvura indwara y’igisukari cyo mu bwoko bwa kabiri (Type 2 diabetes).

Mu igerageza ryakozwe na Novo Nordisk, ibinini bya Wegovy byagaragaje impuzandengo y’igabanuka ry’ibiro rya 16.6%, nk’uko iyi sosiyete yabitangaje ku wa Mbere.

Yongeyeho ko hafi kimwe cya gatatu cy’abagera ku 1,300 bayigeragerejweho bagabanyije ibiro ku kigero cya 20% cyangwa birenzeho.

Biteganyijwe ko ibi binini bizatangira gushyirwa ku isoko ry’Amerika mu ntangiriro za Mutarama 2026.

Umuyobozi mukuru wa Novo Nordisk, Mike Doustdar, yagize ati: “Abarwayi bazabona ibinini byoroshye bifatwa rimwe ku munsi, bishobora kubafasha kugabanya ibiro bingana n’ibyagerwagaho bakoresheje inshinge za Wegovy.”

Ibi binini bishya bishobora kongera umusaruro w’igurishwa rya Novo Nordisk, nyuma y’umwaka utari woroshye wagize ingaruka ku migabane ya yo kubera impungenge ku nyungu z’iyi sosiyete.

Novo Nordisk kandi ihanganye mu irushanwa rikomeye mu isoko ry’imiti yo kugabanya ibiro, rituruka ku zindi sosiyete nka Eli Lilly.

Nyuma y’itangazwa ry’iyi nkuru, imigabane ya Novo Nordisk yazamutse hafi 10% mu bucuruzi bwabaye nyuma yo gufunga isoko ry’imigabane i New York.